HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

Abstract : Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03009918
Contributor : Dominique Figarella-Branger Connect in order to contact the contributor
Submitted on : Tuesday, November 17, 2020 - 2:49:40 PM
Last modification on : Wednesday, November 3, 2021 - 9:56:33 AM

Links full text

Identifiers

Collections

Citation

Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, et al.. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research, American Association for Cancer Research, 2020, 26 (3), pp.552-557. ⟨10.1158/1078-0432.CCR-19-2109⟩. ⟨hal-03009918⟩

Share

Metrics

Record views

28